Xcout Intel
Endeavor Biomedicines, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Endeavor Biomedicines, Inc. among biotechnology companies — ranked by similarity to what Endeavor Biomedicines, Inc. actually does, not by market-cap band.
Subscribe to see Endeavor Biomedicines, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Endeavor Biomedicines, Inc.
Endeavor BioMedicines, Inc. is a San Diego-based biotechnology company focused on developing novel treatments for conditions such as fibrosis.
Endeavor Biomedicines, Inc. at a glance
Endeavor Biomedicines, Inc. is a biotechnology company headquartered in United States. It has raised at least $233.6M across the 2 funding rounds on record. Its most recent funding round, Series C, raised $132.6M in April 2024. Xcout tracks 13 named people at Endeavor Biomedicines, Inc., including Enoch Kariuki (President).
Endeavor Biomedicines, Inc. leadership
- Enoch KariukiPresident
- Chris KruegerChief Operating Officer
- Vishaal TurakhiaChief Financial Officer
- Lisa Lancaster, MDChief Medical Officer
- John HoodCo-Founder & Chief Executive Officer
- Miguel de los RiosCo-Founder & Chief Scientific Officer
7 more named people on record for Endeavor Biomedicines, Inc., with roles, board committees and tenure — see the full roster →
Endeavor Biomedicines, Inc. funding rounds
At least $233.6M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $132.6M | 13 named | |
| Series C | $101M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Endeavor Biomedicines, Inc. competitors
Ranked by semantic similarity — how close each company is to Endeavor Biomedicines, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Similar biotechnology company
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company located in Mission Viejo, California, focused on developing a platform of compounds for biodefense and fibrosis applications.
Similar biotechnology company
MDI Therapeutics, Inc. is a pharmaceutical company headquartered in Novi, Michigan. The company specializes in researching and developing novel therapeutics for the treatment of fibrosis and related fibrotic diseases.
Similar biotechnology company
4F Biotech is a biotechnology firm focused on developing innovative therapeutic approaches, screening platforms, and diagnostic tools to combat fibrosis and inflammatory processes.
Similar biotechnology company
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Similar biotechnology company
Endurance Biotech, Inc. is a biopharmaceutical company that develops first-in-class oral small molecules designed to restore mitochondrial and lysosomal function for the treatment of neurodegenerative, metabolic, and age-related diseases. Its lead clinical program, T-168, targets Parkinson's disease by addressing interconnected cellular systems, reducing neuroinflammation, and enhancing autophagy.
Similar biotechnology company
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, with additional operations in San Diego, California. The company focuses on the discovery and development of novel biopharmaceuticals for cardiovascular and other severe diseases.
Biotechnology / Life Science
Engitix is a biotechnology company that utilizes a proprietary platform based on human Extracellular Matrix (ECM) scaffolds to model and study disease biology. The company develops discovery-stage therapeutics targeting fibrosis, inflammation, and solid tumors, and forms partnerships with pharmaceutical and biotech organizations.
Biotech
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Similar biotechnology company
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Similar biotechnology company
AllRock Bio is a clinical-stage biotechnology company headquartered in Natick, Massachusetts, dedicated to developing transformative therapies for cardiopulmonary and fibrotic conditions.
Similar biotechnology company
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Endeavor Biomedicines, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Endeavor Biomedicines, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →